Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new study shows.
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback